{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:37:46Z","timestamp":1788910666745,"version":"build-2803163510"},"reference-count":120,"publisher":"Georg Thieme Verlag KG","issue":"05","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Baxalta US Inc., a Takeda company"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Congenital haemophilia A (HA) is caused by deficiency of coagulation factor VIII (FVIII) activity, leading to spontaneous or traumatic bleeding events. While FVIII replacement therapy can treat and prevent bleeds, approximately 30% of patients with severe HA develop inhibitor antibodies that render FVIII replacement therapy ineffective. The bypassing agents (BPAs), activated prothrombin complex concentrate (aPCC) and recombinant activated FVII, first approved in 1977 and 1996, respectively, act to generate thrombin independent of pathways that involve factors IX and VIII. Both may be used in patients with congenital haemophilia and inhibitors (PwHIs) for the treatment and prevention of acute bleeds and quickly became standard of care. However, individual patients respond differently to different agents. While both agents are approved for on-demand treatment and perioperative management for patients with congenital haemophilia with inhibitors, aPCC is currently the only BPA approved worldwide for prophylaxis in PwHI. Non-factor therapies (NFTs) have a mechanism of action distinct from BPAs and have reported higher efficacy rates as prophylactic regimens. Nonetheless, treatment challenges remain with NFTs, particularly regarding the potential for synergistic action on thrombin generation with concomitant use of other haemostatic agents, such as BPAs, for the treatment of breakthrough bleeds and in perioperative management. Concomitant use of NFTs with other haemostatic agents could increase the risk of adverse events such as thromboembolic events or thrombotic microangiopathy. This review focuses on the origins, development and on-going role of aPCC in the evolving treatment landscape in the management of PwHI.<\/jats:p>","DOI":"10.1055\/a-1159-4273","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T23:22:44Z","timestamp":1595892164000},"page":"606-620","source":"Crossref","is-referenced-by-count":7,"title":["Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors"],"prefix":"10.1055","volume":"40","author":[{"given":"Hans H.","family":"Brackmann","sequence":"additional","affiliation":[{"name":"Haemophilia Center, Institute of Experimental Haematology and Blood Transfusion, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schramm","sequence":"additional","affiliation":[{"name":"Rudolf Marx-Stiftung f\u00fcr H\u00e4mostaseologie, Universit\u00e4t M\u00fcnchen and Bluterbetreuung Bayern e. V. (BBB) - Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Oldenburg","sequence":"additional","affiliation":[{"name":"Haemophilia Center, Institute of Experimental Haematology and Blood Transfusion, University of Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viridiana","family":"Cano","sequence":"additional","affiliation":[{"name":"Shire International GmbH, a Takeda company, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[{"name":"Baxalta Innovations GmbH, a Takeda company, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"N\u00e9grier","sequence":"additional","affiliation":[{"name":"Haemophilia and Thrombosis Centre, Louis Pradel Hospital, University Claude Bernard Lyon 1, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"02","key":"ref1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/mp.55.2.127","article-title":"Haemophilia A and haemophilia B: molecular insights","volume":"55","author":"D J Bowen","year":"2002","journal-title":"Mol Pathol"},{"issue":"07","key":"ref2","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood-2003-05-1457","article-title":"Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors","volume":"103","author":"J M Soucie","year":"2004","journal-title":"Blood"},{"issue":"03","key":"ref3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2516.1999.00311.x","article-title":"German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies","volume":"5","author":"H H Brackmann","year":"1999","journal-title":"Haemophilia"},{"issue":"02","key":"ref4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)","volume":"160","author":"P W Collins","year":"2013","journal-title":"Br J Haematol"},{"issue":"04","key":"ref5","first-page":"575","article-title":"Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy","volume":"12","author":"A Rocino","year":"2014","journal-title":"Blood Transfus"},{"issue":"01","key":"ref6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"A Srivastava","year":"2013","journal-title":"Haemophilia"},{"issue":"05","key":"ref7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/hae.12730","article-title":"US guidelines for immune tolerance induction in patients with haemophilia a and inhibitors","volume":"21","author":"L A Valentino","year":"2015","journal-title":"Haemophilia"},{"issue":"06","key":"ref8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"M J Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"03","key":"ref9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/rth2.12202","article-title":"Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries","volume":"3","author":"K Usuba","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"05","key":"ref10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/hae.12188","article-title":"Population pharmacokinetics of recombinant factor IX: implications for dose tailoring","volume":"19","author":"S Bj\u00f6rkman","year":"2013","journal-title":"Haemophilia"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00228-009-0676-x","article-title":"Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A","volume":"65","author":"S Bj\u00f6rkman","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"05","key":"ref12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"K Nogami","year":"2019","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","article-title":"Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs","volume":"339","author":"S Ehrenforth","year":"1992","journal-title":"Lancet"},{"issue":"05","key":"ref15","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1365-2516.2009.02039.x","article-title":"Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006)","volume":"15","author":"M Chitlur","year":"2009","journal-title":"Haemophilia"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1182\/blood.V89.3.1115","article-title":"Nephrotic syndrome as a complication of immune tolerance in hemophilia B","volume":"89","author":"B M Ewenstein","year":"1997","journal-title":"Blood"},{"issue":"102","key":"ref17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2516.2008.01923.x","article-title":"Inhibitor development: patient-determined risk factors","volume":"16","author":"J Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1365-2516.2010.02231.x","article-title":"Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report","volume":"16","author":"J Astermark","year":"2010","journal-title":"Haemophilia"},{"issue":"07","key":"ref19","first-page":"740","article-title":"Identifying nongenetic risk factors for inhibitor development in severe hemophilia a","volume":"39","author":"S C Gouw","year":"2013","journal-title":"SeminThrombHemost"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-06-160432","article-title":"How we treat a hemophilia A patient with a factor VIII inhibitor","volume":"113","author":"C L Kempton","year":"2009","journal-title":"Blood"},{"issue":"04","key":"ref21","doi-asserted-by":"crossref","first-page":"E46","DOI":"10.3390\/jcm6040046","article-title":"Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII\/IX","volume":"6","author":"A Rocino","year":"2017","journal-title":"J Clin Med"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/jth.12990","article-title":"Inhibitor development and mortality in non-severe hemophilia A","volume":"13","author":"C L Eckhardt","year":"2015","journal-title":"J ThrombHaemost"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ajh.23957","article-title":"Impact of inhibitors on hemophilia A mortality in the United States","volume":"90","author":"C E Walsh","year":"2015","journal-title":"Am J Hematol"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"M Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"23","key":"ref26","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","article-title":"Toward optimal therapy for inhibitors in hemophilia","volume":"124","author":"C L Kempton","year":"2014","journal-title":"Blood"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/MBC.0000000000000525","article-title":"Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate)","volume":"27","author":"C N\u00e9grier","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"ref30","first-page":"CD004449","article-title":"Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors","author":"D Matino","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"J Astermark","year":"2007","journal-title":"Blood"},{"issue":"10","key":"ref32","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1001\/jama.1969.03160100038010","article-title":"Prothrombin concentrates in treatment of Christmas disease and allied disorders","volume":"208","author":"F AJ Breen Jr","year":"1969","journal-title":"JAMA"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1001\/archinte.1977.03630210083025","article-title":"Prothrombin complex concentrate","volume":"137","author":"R T DeWitt","year":"1977","journal-title":"Arch Intern Med"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM197407252910402","article-title":"Activated prothrombin concentrate for patients with factor VIII inhibitors","volume":"291","author":"E M Kurczynski","year":"1974","journal-title":"N Engl J Med"},{"issue":"20","key":"ref35","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1056\/NEJM197411142912014","article-title":"Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate","volume":"291","author":"Y Sultan","year":"1974","journal-title":"N Engl J Med"},{"issue":"18","key":"ref36","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.1976.03270190017020","article-title":"Antihemophilic factor inhibitors. Management with prothrombin complex concentrates","volume":"236","author":"P Kelly","year":"1976","journal-title":"JAMA"},{"issue":"03","key":"ref37","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0049-3848(82)90240-7","article-title":"Activated prothrombin complex concentrates: approaches to their preparation","volume":"25","author":"C V Prowse","year":"1982","journal-title":"Thromb Res"},{"issue":"05","key":"ref38","first-page":"331","article-title":"Update on the mechanism of action and future of activated prothrombin complex concentrates","volume":"3","author":"P L Turecek","year":"2004","journal-title":"CurrHematol Rep"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1365-2516.2006.01379.x","article-title":"The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor","volume":"12","author":"C N\u00e9grier","year":"2006","journal-title":"Haemophilia"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/hae.12873","article-title":"Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(\u00ae) in prophylactic therapy","volume":"22","author":"K Varadi","year":"2016","journal-title":"Haemophilia"},{"issue":"S 02","key":"ref42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"P L Turecek","year":"2004","journal-title":"Haemophilia"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.V61.1.36.36","article-title":"The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors","volume":"61","author":"M W Hilgartner","year":"1983","journal-title":"Blood"},{"issue":"18","key":"ref44","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"C Leissinger","year":"2011","journal-title":"N Engl J Med"},{"issue":"03","key":"ref45","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2516.2011.02693.x","article-title":"Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey","volume":"18","author":"B Z\u00fclfikar","year":"2012","journal-title":"Haemophilia"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","article-title":"Inhibitor development in haemophilia B: an orphan disease in need of attention","volume":"138","author":"D DiMichele","year":"2007","journal-title":"Br J Haematol"},{"issue":"03","key":"ref47","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1111\/hae.12080","article-title":"SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies","volume":"19","author":"C N\u00e9grier","year":"2013","journal-title":"Haemophilia"},{"issue":"04","key":"ref48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2006.01284.x","article-title":"A retrospective postlicensure survey of FEIBA efficacy and safety","volume":"12","author":"D Dimichele","year":"2006","journal-title":"Haemophilia"},{"issue":"01","key":"ref49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/hae.12246","article-title":"Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors","volume":"20","author":"S V Antunes","year":"2014","journal-title":"Haemophilia"},{"issue":"03","key":"ref50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hae.12602","article-title":"Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors","volume":"21","author":"N Ewing","year":"2015","journal-title":"Haemophilia"},{"issue":"03","key":"ref51","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/hae.12608","article-title":"Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres","volume":"21","author":"C Nakar","year":"2015","journal-title":"Haemophilia"},{"issue":"S 01","key":"ref52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000056717","article-title":"Induction of immune tolerance in haemophilia A inhibitor patients by the \u2018Bonn Protocol\u2019: predictive parameter for therapy duration and outcome","volume":"77","author":"J Oldenburg","year":"1999","journal-title":"Vox Sang"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(77)90871-6","article-title":"Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder","volume":"2","author":"H H Brackmann","year":"1977","journal-title":"Lancet"},{"issue":"S 01","key":"ref54","first-page":"30","article-title":"Immune tolerance for the treatment of factor VIII inhibitors--twenty years' \u2018bonn protocol\u2019","volume":"70","author":"H H Brackmann","year":"1996","journal-title":"Vox Sang"},{"key":"ref55","first-page":"181","article-title":"Induced immunotolerance in factor VIII inhibitor patients","volume":"150","author":"H H Brackmann","year":"1984","journal-title":"ProgClinBiol Res"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1182\/blood-2004-05-1811","article-title":"Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept","volume":"105","author":"H Zeitler","year":"2005","journal-title":"Blood"},{"issue":"26","key":"ref57","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/bloodadvances.2017011536","article-title":"Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data","volume":"1","author":"M Rota","year":"2017","journal-title":"Blood Adv"},{"issue":"S 02","key":"ref58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2004.00935.x","article-title":"FEIBA safety profile in multiple modes of clinical and home-therapy application","volume":"10","author":"H Luu","year":"2004","journal-title":"Haemophilia"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JBM.S63265","article-title":"Physical and psychosocial challenges in adult hemophilia patients with inhibitors","volume":"5","author":"S duTreil","year":"2014","journal-title":"J Blood Med"},{"issue":"09","key":"ref60","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/j.1538-7836.2009.03538.x","article-title":"The molecular mechanisms of immunomodulation and tolerance induction to factor VIII","volume":"7","author":"B Waters","year":"2009","journal-title":"J ThrombHaemost"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1182\/blood-2014-04-566786","article-title":"Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses","volume":"125","author":"Y C Kim","year":"2015","journal-title":"Blood"},{"issue":"01","key":"ref62","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13023-018-0800-z","article-title":"European principles of inhibitor management in patients with haemophilia","volume":"13","author":"P LF Giangrande","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"06","key":"ref63","first-page":"1113","article-title":"Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity","volume":"77","author":"C N\u00e9grier","year":"1997","journal-title":"ThrombHaemost"},{"issue":"01","key":"ref64","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2516.2009.02116.x","article-title":"Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series","volume":"16","author":"C E Ettingshausen","year":"2010","journal-title":"Haemophilia"},{"issue":"05","key":"ref65","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjh.15175","article-title":"Activated prothrombin complex concentrate (FEIBA\u00ae) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry","volume":"184","author":"E Zanon","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"ref66","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","article-title":"Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors","volume":"7","author":"A Coppola","year":"2009","journal-title":"J ThrombHaemost"},{"issue":"01","key":"ref67","first-page":"52","article-title":"The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"D M DiMichele","year":"2002","journal-title":"ThrombHaemost"},{"key":"ref68","first-page":"45","article-title":"The German Registry of immune tolerance treatment in hemophilia--1999 update","volume":"85","author":"H Lenk","year":"2000","journal-title":"Haematologica"},{"issue":"11","key":"ref69","first-page":"1186","article-title":"Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success","volume":"86","author":"G Mariani","year":"2001","journal-title":"Haematologica"},{"issue":"05","key":"ref70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2042098611415566","article-title":"Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes","volume":"2","author":"A D Shapiro","year":"2011","journal-title":"Ther Adv Drug Saf"},{"issue":"S 01","key":"ref71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2005.01156.x","article-title":"Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography","volume":"11","author":"B S\u00f8rensen","year":"2005","journal-title":"Haemophilia"},{"issue":"11","key":"ref72","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1046\/j.1538-7836.2003.00450.x","article-title":"Monitoring the bioavailability of FEIBA with a thrombin generation assay","volume":"1","author":"K V\u00e1radi","year":"2003","journal-title":"J ThrombHaemost"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1182\/blood-2019-124324","article-title":"Real world clinical management of patients with hemophilia and inhibitors: effectiveness and safety of aPCC in patients with >18 months' follow-up in the FEIBA Global Outcome study (FEIBA GO)","volume":"134","author":"J Windyga","year":"2019","journal-title":"Blood"},{"key":"ref74","first-page":"119","article-title":"Tolerability\/safety of FEIBA reconstituted in regular or 50% reduced volume and faster infusion rates: rationale and study design in patients with hemophilia A or B with inhibitors","volume":"24","author":"T MCR Ali","year":"2018","journal-title":"Haemophilia"},{"issue":"01","key":"ref75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","article-title":"Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors","volume":"15","author":"E Berntorp","year":"2009","journal-title":"Haemophilia"},{"issue":"09","key":"ref77","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"J Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"01","key":"ref78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2017-09-743385","article-title":"Novel therapeutics for hemophilia and other bleeding disorders","volume":"132","author":"M U Callaghan","year":"2018","journal-title":"Blood"},{"issue":"09","key":"ref79","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"ref80","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1182\/bloodadvances.2019000228","article-title":"Emicizumab use in major orthopedic surgery","volume":"3","author":"C D Seaman","year":"2019","journal-title":"Blood Adv"},{"issue":"08","key":"ref81","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.3324\/haematol.2018.215129","article-title":"Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement","volume":"104","author":"E Santagostino","year":"2019","journal-title":"Haematologica"},{"key":"ref82","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1182\/blood-2018-99-115089","article-title":"Maintaining perioperative hemostasis in patients with severe hemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"132","author":"K Zimowski","year":"2018","journal-title":"Blood"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V130.Suppl_1.89.89","article-title":"Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2)","volume":"130","author":"R Kruse-Jarres","year":"2017","journal-title":"Blood"},{"issue":"02","key":"ref84","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1111\/hae.13689","article-title":"Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors","volume":"25","author":"D F Brophy","year":"2019","journal-title":"Haemophilia"},{"issue":"04","key":"ref85","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.3324\/haematol.2017.185330","article-title":"Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab","volume":"103","author":"Y Dargaud","year":"2018","journal-title":"Haematologica"},{"issue":"25","key":"ref86","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Y Dargaud","year":"2010","journal-title":"Blood"},{"issue":"02","key":"ref87","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1751-553X.2007.01022.x","article-title":"The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents","volume":"31","author":"J J van Veen","year":"2009","journal-title":"Int J Lab Hematol"},{"issue":"01","key":"ref88","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/hae.12309","article-title":"Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors","volume":"20","author":"H Luna-Z\u00e1izar","year":"2014","journal-title":"Haemophilia"},{"issue":"01","key":"ref89","first-page":"16","article-title":"Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay","volume":"33","author":"P L Turecek","year":"2003","journal-title":"PathophysiolHaemostThromb"},{"key":"ref90","first-page":"116","article-title":"A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results","volume":"3","author":"V Jim\u00e9nez-Yuste","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"R Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"22","key":"ref92","first-page":"2194","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"J Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"04","key":"ref93","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non-factor replacement therapies in hemophilia","volume":"37","author":"A Tiede","year":"2017","journal-title":"Hamostaseologie"},{"issue":"04","key":"ref94","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2516.2006.01284.x","article-title":"A retrospective postlicensure survey of FEIBA efficacy and safety","volume":"12","author":"D Dimichele","year":"2006","journal-title":"Haemophilia"},{"issue":"06","key":"ref95","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/hae.13612","article-title":"Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study","volume":"24","author":"J Mahlangu","year":"2018","journal-title":"Haemophilia"},{"issue":"22","key":"ref96","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1056\/NEJMc1712683","article-title":"Emicizumab Prophylaxis in Hemophilia A with Inhibitors","volume":"377","author":"L M Aledort","year":"2017","journal-title":"N Engl J Med"},{"key":"ref98","first-page":"10","article-title":"Management of bleed events in the phase I study of fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia in patients with and without inhibitors","volume":"23","author":"S GP Rangarajan","year":"2017","journal-title":"Haemophilia"},{"key":"ref99","first-page":"107","article-title":"Thromboelastography may be useful for tailoring treatment of breakthrough bleeds in patients on prophylaxis with Concizumab","volume":"25","author":"I Fernandez-Bello","year":"2019","journal-title":"Haemophilia"},{"key":"ref100","first-page":"43","article-title":"In vitro activity of concizumab in combination with activated prothrombin complex concentrate or rFVIIa as studied by thromboelastography and thrombin generation","volume":"24","author":"C Augustsson","year":"2018","journal-title":"Haemophilia"},{"issue":"03","key":"ref101","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jth.14380","article-title":"Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits","volume":"17","author":"B Lauritzen","year":"2019","journal-title":"J Thromb Haemost"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1182\/blood.V128.22.4980.4980","article-title":"Long-term prophylaxis with activated recombinant FVII in children with hemophilia A and inhibitor, receiving treatment with ITI protocol","volume":"128","author":"E PV Shiller","year":"2016","journal-title":"Blood"},{"issue":"02","key":"ref104","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1177\/1076029614555902","article-title":"A comparison of efficacy between recombinant activated factor VII (Aryoseven) and novoseven in patients with hereditary FVIII deficiency with inhibitor","volume":"22","author":"M Faranoush","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"issue":"01","key":"ref105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hae.13050","article-title":"A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors","volume":"23","author":"Y Shinkoda","year":"2017","journal-title":"Haemophilia"},{"key":"ref107","first-page":"85","article-title":"A phase 1b\/2 study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PF-06741086, an anti-TFPI monoclonal antibody, in patients with severe hemophilia A or B","volume":"3","author":"J Mahlangu","year":"2019","journal-title":"Res PractThrombHaemost"},{"issue":"10","key":"ref108","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/jth.14247","article-title":"Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia","volume":"16","author":"R A Gruppo","year":"2018","journal-title":"J ThrombHaemost"},{"key":"ref109","first-page":"86","article-title":"Phase 2\/3 trial of subcutaneous engineered FVIIa marzeptacoga Lfa (activated) in hemophilia A or B with inhibitors: efficacy, safety and pharmacokinetics","volume":"3","author":"J Mahlangu","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"01","key":"ref112","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/asheducation-2017.1.587","article-title":"Hemophilia gene therapy comes of age","volume":"2017","author":"L A George","year":"2017","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"07","key":"ref113","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1055\/s-0039-1688445","article-title":"Gene therapy: paving new roads in the treatment of hemophilia","volume":"45","author":"G G Yamaguti-Hayakawa","year":"2019","journal-title":"Semin Thromb Hemost"},{"issue":"12","key":"ref115","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"A D Shapiro","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref116","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hae.13817","article-title":"Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra\u00ae): proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP)","volume":"25","author":"S Susen","year":"2019","journal-title":"Haemophilia"},{"issue":"03","key":"ref117","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hae.13495","article-title":"Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee","volume":"24","author":"P W Collins","year":"2018","journal-title":"Haemophilia"},{"issue":"02","key":"ref118","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"R Ljung","year":"2019","journal-title":"Eur J Haematol"},{"issue":"03","key":"ref119","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.15942","article-title":"How I treat children with haemophilia and inhibitors","volume":"186","author":"G Young","year":"2019","journal-title":"Br J Haematol"},{"issue":"13","key":"ref120","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJM198109243051301","article-title":"The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial","volume":"305","author":"L J Sjamsoedin","year":"1981","journal-title":"N Engl J Med"},{"issue":"07","key":"ref121","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1046\/j.1537-2995.1990.30790385521.x","article-title":"Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients","volume":"30","author":"M Hilgartner","year":"1990","journal-title":"Transfusion"},{"issue":"02","key":"ref122","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"H J Ehrlich","year":"2002","journal-title":"Haemophilia"},{"issue":"04","key":"ref123","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1067\/mtc.2002.126038","article-title":"Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII","volume":"124","author":"J D Bui","year":"2002","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"05","key":"ref124","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1055\/s-0037-1613110","article-title":"Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient","volume":"87","author":"S B Rosenfeld","year":"2002","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref125","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2516.2007.01451.x","article-title":"Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience","volume":"13","author":"J Schneiderman","year":"2007","journal-title":"Haemophilia"},{"issue":"11","key":"ref126","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A","volume":"16","author":"H Eichler","year":"2018","journal-title":"J ThrombHaemost"},{"issue":"05","key":"ref127","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"P Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"05","key":"ref128","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"A Sehgal","year":"2015","journal-title":"Nat Med"},{"issue":"09","key":"ref129","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"K J Pasi","year":"2017","journal-title":"N Engl J Med"},{"issue":"04","key":"ref130","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","article-title":"Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys","volume":"19","author":"J M Gu","year":"2017","journal-title":"AAPS J"},{"issue":"06","key":"ref131","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/hae.12205","article-title":"A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics\/pharmacodynamics","volume":"19","author":"A Shirahata","year":"2013","journal-title":"Haemophilia"},{"issue":"06","key":"ref132","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/hae.13357","article-title":"Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors","volume":"23","author":"J Ducore","year":"2017","journal-title":"Haemophilia"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1159-4273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T19:29:02Z","timestamp":1667590142000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1159-4273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":120,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2020,12,29]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1159-4273","relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]}}}